Professor Tony Mok, Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong, is widely regarded as one of Asia’s top experts in lung cancer management. In this recent webinar hosted by Roche Diagnostics Asia Pacific, he describes how multidisciplinary teams can optimise treatment plans for patients with non-small cell lung cancer (NSCLC), including the roughly 5% of patients who are ALK-positive. Professor Mok focuses on why various modalities of testing are important due to tumour heterogeneity, and how a greater selection of tyrosine kinase inhibitors could be advantageous in various aspects, as demonstrated by the Global ALEX study.

Some of the key topics covered in Professor Mok’s presentation include the following:

Adopting and combining accurate diagnostics tools to aid decision making [02:52]
Administering 2nd and 3rd generation TKI therapy [09:10]
Combating mutations (e.g. G1202R) that gives rise to resistance [16:42]

Watch the full presentation below.